Compare OCC & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | QTTB |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8M | 44.3M |
| IPO Year | 1996 | N/A |
| Metric | OCC | QTTB |
|---|---|---|
| Price | $4.88 | $3.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 96.5K | ★ 172.4K |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,038,213.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.54 | N/A |
| 52 Week Low | $2.40 | $1.35 |
| 52 Week High | $11.50 | $6.37 |
| Indicator | OCC | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 51.99 |
| Support Level | $4.56 | $3.78 |
| Resistance Level | $5.35 | $4.31 |
| Average True Range (ATR) | 0.48 | 0.33 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 38.04 | 46.35 |
Optical Cable Corp manufactures tight-buffered fiber optic & copper data communication cables, data communication connectivity solutions for enterprise markets, and customized solutions for specialty use & harsh environments. Its products and services include designs and customized products for specialty applications and harsh environments, cabling, connectors, patch cords, assemblies, racks, cabinets, datacom enclosures, patch panels, faceplates, and multi-media boxes. The company supplies its products and services to industries such as the military, industrial, mining, petrochemical, renewable energy and broadcast applications, and for the wireless carrier market.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.